鸡用禽适应型自扩增mRNA疫苗配方的评估
研究构建两种Tembusu病毒(TMUV)复制子并比较其与VEEV复制子在体外及鸡体内的表现。TMUV复制子在禽与哺乳动物细胞中转基因表达更强更持久、细胞病变更轻。鸡免疫试验中TMUV复制子RNA诱导IBDV特异性血清阳转,而VEEV复制子RNA无显著体液反应;AIV研究中两者均未能诱导体液反应,VEEV DREP产生的(中和)抗体反应最高。
要点
- TMUV复制子在体外转基因表达强于且持久于VEEV复制子,细胞病变更轻。
- 鸡免疫试验中TMUV复制子RNA诱导IBDV特异性血清阳转,VEEV复制子RNA无显著体液反应。
- AIV免疫中TMUV与VEEV复制子RNA均未能诱导体液反应,VEEV DREP抗体反应最高。
核心结论
- TMUV复制子RNA可在鸡体内诱导IBDV特异性血清阳转,而VEEV复制子RNA无显著体液反应。
- AIV与IBDV免疫研究中VEEV DREP均产生最高的(中和)抗体反应,凸显自扩增mRNA疫苗技术应对家禽新发疾病的潜力。
研究设计与样本
- 研究构建两种编码不同衣壳基因长度的Tembusu病毒(TMUV)复制子,并在体外与基准VEEV复制子比较。
- 同时开发TMUV与VEEV复制子的DNA启动版本(DREP),复制子成功表达AIV血凝素(HA)糖蛋白与IBDV衣壳蛋白(pVP2)。
- 在鸡中开展初免-加强免疫试验,使用脂质纳米颗粒(LNP)配方的复制子RNA与DREP,分别编码AIV或IBDV的病毒(糖)蛋白。
主要发现
- TMUV复制子系统在禽与哺乳动物细胞中均显示强而持久的转基因表达,优于VEEV复制子系统。
- TMUV复制子RNA在体外诱导的细胞病变效应小于VEEV复制子RNA。
- AIV免疫中TMUV与VEEV复制子RNA均未能诱导体液反应。
- IBDV免疫中TMUV复制子RNA诱导接种鸡血清阳转,VEEV复制子RNA无显著体液反应。
- AIV与IBDV免疫研究中VEEV DREP产生的(中和)抗体反应最高。
局限性
- 原文指出VEEV TC-83复制子在禽类中效力有限,因此需要探索替代的禽适应复制子平台。
- 原文指出AIV免疫中TMUV与VEEV复制子RNA均未能诱导体液反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Each year, millions of poultry succumb to highly pathogenic avian influenza A virus (AIV) and infectious bursal disease virus (IBDV) infections. Conventional vaccines based on inactivated or live-attenuated viruses are useful tools for disease prevention and control, yet, they often fall short in terms of safety, efficacy, and development times. Therefore, versatile vaccine platforms are crucial to protect poultry from emerging viral pathogens. Self-amplifying (replicon) RNA vaccines offer a well-defined and scalable option for the protection of both animals and humans. The best-studied replicon platform, based on the Venezuelan equine encephalitis virus (VEEV; family Togaviridae) TC-83 vaccine strain, however, displays limited efficacy in poultry, warranting the exploration of alternative, avian-adapted, replicon platforms. In this study, we engineered two Tembusu virus (TMUV; family Flaviviridae) replicons encoding varying capsid gene lengths and compared these to the benchmark VEEV replicon in vitro. The TMUV replicon system exhibited a robust and prolonged transgene expression compared to the VEEV replicon system in both avian and mammalian cells. Moreover, the TMUV replicon induced a lesser cytopathic effect compared to the VEEV replicon RNA in vitro. DNA-launched versions of the TMUV and VEEV replicons (DREP) were also developed. The replicons successfully expressed the AIV haemagglutinin (HA) glycoproteins and the IBDV capsid protein (pVP2). To assess the immune responses elicited by the TMUV replicon system in chickens, a prime-boost vaccination trial was conducted using lipid nanoparticle (LNP)-formulated replicon RNA and DREP encoding the viral (glyco)proteins of AIV or IBDV. Both TMUV and VEEV replicon RNAs were unable to induce a humoral response against AIV. However, TMUV replicon RNA induced IBDV-specific seroconversion in vaccinated chickens, in contrast to VEEV replicon RNA, which showed no significant humoral response. In both AIV and IBDV immunization studies, VEEV DREP generated the highest (neutralizing) antibody responses, which underscores the potential for self-amplifying mRNA vaccine technology to combat emerging poultry diseases.
引用
- Comes JDG, Doets K, Zegers T, et al. Evaluation of bird-adapted self-amplifying mRNA vaccine formulations in chickens. Vaccine. 2024. PMID: 38521674. doi:10.1016/j.vaccine.2024.03.032
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。